Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage

Inclusion Criteria:

1. Age: Male patients aged 18 years and older.
2. Diagnosis: Patients who are suspected of having prostate cancer based on clinical data and standard diagnostic protocols.
3. Disease Stage: Patients at any stage of suspected prostate cancer (localized, locally advanced, or metastatic).
4. Consent: Ability and willingness to provide written informed consent.
5. Clinical Data Availability: Availability of comprehensive clinical data.
6. Sample Provision: Willingness to provide blood and/or tissue samples for genetic and inflammatory marker analysis.

Exclusion Criteria:

1. Prior Treatment: Patients who have undergone any prior prostate cancer treatments such as surgery, radiation therapy, or systemic therapies (e.g., hormone therapy, chemotherapy).
2. Other Malignancies: Presence of other concurrent malignancies, except for adequately treated basal cell or squamous cell skin cancer.
3. Severe Comorbidities: Patients with severe or uncontrolled comorbid conditions that could interfere with study participation or data interpretation (e.g., severe cardiovascular, pulmonary, hepatic, or renal diseases).
4. Infection: Active infections or other severe medical conditions that could compromise patient safety or study integrity.
5. Non-compliance: Inability to comply with study procedures, follow-up requirements, or any condition that, in the investigator's opinion, could interfere with study participation.
6. Medication Use: Use of medications that could interfere with the study results, such as immunosuppressive drugs.

Additional Considerations:

* Screening: All potential participants will undergo a screening process to verify eligibility criteria.
* Confidentiality: Ensure all patient data is handled in accordance with privacy regulations and ethical guidelines.
* Follow-Up: Participants should be willing to attend regular follow-up visits for ongoing data collection and monitoring of disease progression and treatment response.

By setting these criteria, the study aims to create a well-defined patient cohort for evaluating the relationship between genetic and inflammatory markers and prostate cancer aggressiveness.